The present disclosure relates to near-infrared (NIR) photoimmunotherapy (PIT) for treating a subject having a cancer, such as a cancer comprising a first tumor or a primary tumor, metastatic tumor cells and/or invasive tumor cells. The method includes administering to the subject a targeting molecule that binds CD25 conjugated with phthalocyanine dye, such as IR700, and administering an immune checkpoint inhibitor such as an anti PD-1 antibody, followed by illuminating the first tumor or primary tumor with a wavelength of light suitable for the activation of the phthalocyanine dye.

The invention is directed to a method for determining condition parameters for photodynamic therapy in which after administration of 5-aminolevulinic acids, protoporphyrin IX accumulated in cells is irradiated with light, the method including steps of: calculating, in an experimental phase, a regression curve representing a correlation among three condition parameters: cell viability (Y), intracellular protoporphyrin IX accumulation (X), and light irradiation energy density (P); and selecting in advance, prior to initiation of therapy, two condition parameters from the cell viability (Y), the intracellular protoporphyrin IX accumulation (X), and the light irradiation energy density (P), and then determining the remaining condition parameter using the regression curve. Thus, the photodynamic therapy can be optimized.

Disclosed, according to one embodiment, is a photodynamic therapy method mediated by a chlorin e6 photosensitizer composite for treating and preventing obesity, the method comprising the steps of: injecting or administering a chlorin e6 composite into a subject; and performing photodynamic therapy on the subject into which the chlorin e6 composite has been injected or administered.

[Object] It is an object of the present invention to provide a conjugate of a biotin-modified dimer and a phthalocyanine dye, which is used in photoimmunotherapy.

[Means for Solution] A compound represented by the following formula (1) or a salt thereof:

##STR00001##

wherein X represents a substituent having a hydrophilic group, a cationic group or an amino group at the terminus thereof, or —OH, and other groups have the meanings as defined in the description.

It is an object of the present invention to provide a medicament for killing tumor cells, having few side effects. According to the present invention, provided is a medicament for killing tumor cells that express a target substance at a low level on the cell surface thereof, said medicament comprising: a conjugate of a substance that binds to a target substance on the surface of tumor cells and a cytotoxin; and a photosensitizing dye.

Among the various aspects of the present disclosure is the provision of compositions and methods for targeted treatment of cancers or neoplasms. In particular, the present disclosure is directed to a photodynamic system comprising a nanoparticle conjugated to a photosensitizer that can be activated by an excitation source such as ionizing radiation or other forms of electromagnetic energy.

A method of treating or preventing an intracellular bacterial infection, comprising contacting the cell(s) which are infected with an antibacterial agent and a photosensitizing agent and irradiating the cell(s) with light of a wavelength effective to activate the photosensitizing agent, wherein the antibacterial agent is released into the cytosol of the cell(s) and kills, damages or prevents the replication of bacteria in said cell(s) is described. Related uses, and compositions, products and kits for the same are further described.

There is provided with a porphyrin compound represented by Formula (I) or a salt thereof; ##STR00001## where A is a linking group represented as —X—NHCO— where X is a C.sub.1 to C.sub.6 alkylene group, each of R.sub.1, R.sub.2, R.sub.4, R.sub.5, R.sub.7, R.sub.8, R.sub.10, and R.sub.11 is a hydrogen atom, each of R.sub.3, R.sub.6, and R.sub.9 is a substituent of Formula; R.sub.12 is selected from a group of substituents represented by Formulae, R.sub.13 is a sulfo group, Ra, Rb, and Rc are substituents independently selected from C.sub.1 to C.sub.6 alkyl groups, and Rd is a hydrogen atom or a C.sub.1 to C.sub.6 alkyl group, and Rx is a substituent represented by General Formula. The porphyrin compound is useful as a cancer therapeutic agent, photosensitizer and fluorescent probe.

Various oil-in-water (O/W) nanoemulsions containing an oil phase or oil core, preferably selected from vitamin E or oleic acid, stabilized by a sphingolipid of the sphingomyelin type, and optionally other lipids such as phospholipids, cholesterol, octadecylamine, DOTAP (N-[1-(2,3-Dioleoyloxy) propyl]-N, N, N-trimethylammonium methyl-sulfate), and PEGylated derivatives (derivatives with polyethylene glycol), for use as a nanotech vehicle, for example for the management of cancer and metastatic disease. Said nanoemulsions can be functionalized with ligands capable of interacting or binding to receptors expressed on the cell membrane of tumor cells, and in particular capable of interacting or binding to receptors expressed on the membrane of primary and/or disseminated or metastatic tumor cells. Also, antitumor drugs or therapeutic biomolecules can be encapsulated in said nanoemulsions and, finally, contrast agents can be incorporated for their use in the in vivo diagnosis in said nanoemulsions.

A medical nanoparticle includes a core, an outer lipid layer, an inner lipid layer, a photosensitizer, and a nucleic acid. The core includes a bio-degradable ionic precipitate (BIP). The inner lipid layer is between the core and the outer lipid layer. The photosensitizer is between the inner lipid layer and the outer lipid layer, and the nucleic acid is at the surface of the core.